The newly developed AspID PCR assay for detection of Aspergillus spp. was evalu- and 18 without IPA were investigated. Sensitivity, specificity, positive and negative likelihood ratio for the AspID assay were 94.1% (95% CI 73.3-99.9), 76.5% (95% CI 50.1-93.2), 4 (95% CI 1.7-9.5) and 0.1 (95% CI 0.01-0.5) respectively.
Summary
The newly developed AspID PCR assay for detection of Aspergillus spp. was evaluated with an interlaboratory quality control programme panel and human bronchoalveolar lavage fluid (BALF) samples. With the quality control programme, 8 out of 9 panel members were correctly identified. With the clinical study, 36 BALF samples that had been obtained from 18 patients with invasive pulmonary aspergillosis (IPA) and 18 without IPA were investigated. Sensitivity, specificity, positive and negative likelihood ratio for the AspID assay were 94.1% (95% CI 73.3-99.9), 76.5% (95% CI 50.1-93.2), 4 (95% CI 1.7-9.5) and 0.1 (95% CI 0.01-0.5) respectively.
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| INTRODUC TI ON
Invasive pulmonary aspergillosis (IPA) remains a major cause of morbidity and mortality among severely ill patients. The critical step for successful management of IPA is rapid initiation of antifungal therapy requiring early and reliable diagnosis. 1 
| MATERIAL AND ME THODS
The accuracy of the AspID was determined utilising the QCMD 
| RE SULTS
When the accuracy of the AspID was determined with the QCMD panel, 5 out of 6 Aspergillus positive samples tested positive for
Aspergillus and negative for Aspergillus terreus. The remaining sample turned out to be false negative. The false negative sample contained
Aspergillus fumigatus DNA in a TE buffer solution and was classified as "educational" sample (ie containing low amount of fungal DNA).
All Aspergillus negative samples were correctly identified as negative with the AspID PCR assay.
QCMD panel characteristics and results are displayed in Table 1 , characteristics of patients with and without IPA are displayed in 
| D ISCUSS I ON
In this pilot study, the newly developed AspID PCR assay was evaluated with the 2016 Aspergillus QCMD proficiency panel and with BALF samples from patients at risk for IPA for the first time.
With both the QCMD programme panel and the BALF samples the AspID PCR showed an excellent sensitivity. In this study, the clinical sensitivity of AspID was 94%, which is higher to that of PCR assays for IPA diagnosis reported in other studies. 8, 9, 18 This may be due to the classification approach used in this study as a BALF-GM >3 ODI was required for IPA diagnosis. A higher BALF-GM level may TA B L E 2 Characteristics of the study population providing clinical samples
